Evidence map›Paper›PMID 32605315›Full record

ArticleCancers2020

Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes.

Timothy J Lavelle, Tine Norman Alver, Karen-Marie Heintz, Patrik Wernhoff, Vegard Nygaard, Sigve Nakken, Geir Frode Øy, Sigurd Leinæs Bøe, Alfonso Urbanucci, Eivind Hovig

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Timothy J LavelleDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Tine Norman AlverDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Karen-Marie HeintzDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Patrik WernhoffDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Vegard NygaardDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Sigve NakkenDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Geir Frode ØyDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Sigurd Leinæs BøeDepartment of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, 0424 Oslo, Norway.
Alfonso UrbanucciDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Eivind HovigDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Oslo University Hospital · NO

Funding

Kreftforeningen 198016-2018
6 · The paper itself

Abstract

The MC1R/cAMP/MITF pathway is a key determinant for growth, differentiation, and survival of melanocytes and melanoma. MITF-M is the melanocyte-specific isoform of Microphthalmia-associated Transcription Factor (MITF) in human melanoma. Here we use two melanocyte cell lines to show that forced expression of hemagglutinin (HA) -tagged MITF-M through lentiviral transduction represents an oncogenic insult leading to consistent cell transformation of the immortalized melanocyte cell line Hermes 4C, being a melanocortin-1 receptor (MC1R) compound heterozygote, while not causing transformation of the MC1R wild type cell line Hermes 3C. The transformed HA-tagged MITF-M transduced Hermes 4C cells form colonies in soft agar and tumors in mice. Further, Hermes 4C cells display increased MITF chromatin binding, and transcriptional reprogramming consistent with an invasive melanoma phenotype. Mechanistically, forced expression of MITF-M drives the upregulation of the AXL tyrosine receptor kinase (AXL), with concomitant downregulation of phosphatase and tensin homolog (PTEN), leading to increased activation of the PI3K/AKT pathway. Treatment with AXL inhibitors reduces growth of the transformed cells by reverting AKT activation. In conclusion, we present a model system of melanoma development, driven by MITF-M in the context of MC1R loss of function, and independent of UV exposure. This model provides a basis for further studies of critical changes in the melanocyte transformation process.

Indexed as

AXL inhibitorfamilial melanomaMC1Rmelanocyte transformationmelanomaMITF

Identifiers

PMID32605315
PMCPMC7408466
OpenAlexW3037886932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.